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was inadequate response from traditional disease-modifying anti-rheumatic drugs 
(DMARDs) alone (54.9%), followed by symptom control (13.4%). Among the remaining 
responses, clinical data (e.g., results from clinical trials) was cited most frequently in 
the UK (17.1%) compared to Germany/Spain (9.0%/4.7%), while personal experience 
was cited most in Germany (15.3%) vs. UK/Spain (2.7%/0.9%). Inadequate response 
to DMARDs was most frequently reported for adalimumab (61.5%) vs. etanercept 
(46.9%) or other biologics (40.2%); inadequate DMARD symptom control was more 
cited for etanercept (18.8%) vs. adalimumab (11.1%) or other biologics (9.8%). Among 
the 23 patients who switched to a second biologic agent, 72.7% were switched due 
to inadequate response to the first biologic agent. ConClusions: Across the 
three study countries, prescribers most frequently initiated biologic therapy due 
to inadequate response or lack of symptom control on traditional DMARDs. Other 
reasons varied by country, however differences across biologic agents prescribed 
were minimal.
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objeCtives: Cervical Dystonia (CD), the most common adult-onset dystonia, is 
characterised by involuntary contractions of the cervical muscles that result in 
abnormal, sustained, and painful postures of the head, neck and shoulders. Annual 
prevalence rate of CD in Europe is approximately 117 per million. To date, very 
few studies assessed the burden of the disease, and those published focused on 
costs of specific treatments. The objective of this study was to describe health care 
resource utilisation of patients with CD during the first year after diagnosis in 
the UK. Methods: In this retrospective cohort study, adult patients with a first 
ever diagnosis of primary or secondary CD (Read code: F138200 Spasmodic torti-
collis) between January 2007 and December 2011 were selected from The Health 
Improvement Network (THIN), a large UK Primary Care database. Patients were 
required to have a follow-up time of at least 24 months after diagnosis. Analyses 
performed described demographic and clinical characteristics at diagnosis and 
all-cause utilization of CD-related health care resources including treatment dur-
ing follow up. Results: This study included 4,497 patients, 65.40% were female, 
median age at diagnosis was 41 years old and 8.05% were diagnosed with depression. 
During that first year, patients had on average 6 visits to the GP (SD: 5.45) and were 
newly referred most frequently to the orthopaedist (5.09%); less than 2% of patients 
had an all-cause hospitalisation and less than 1% underwent neurosurgery; 80.23% 
were managed with pharmacological treatment for CD, and the most commonly 
prescribed drugs were analgesics (69.85%) and benzodiazepines (41.23%); 14.65% 
received physical therapy. ConClusions: This study provides first-time estimates 
of the health care resource utilisation related to management of patients with CD 
in UK during the first year. To describe the complete burden of CD further research 
will have to investigate secondary care data and longer time horizon.
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objeCtives: To analyze the potential cost savings associated with utilization of 
a quota for biosimilar RA medicines in a biologic naïve but potentially biologic 
eligible population (those defined as severe). Methods: High patient numbers 
in rheumatoid arthritis (RA) and biologic therapy costs place significant pressures 
on health care budgets. Currently biologic therapies are underutilized in severe RA 
(DAS Score ≥ 3.7) patient populations that may be eligible for treatment. Biosimilar 
treatments are expected to reach the market (for the top 3 molecules adalimumab, 
etanercept and infliximab) by 2017 and may provide an avenue to reduce treatment 
costs and increase patient access to these agents. Biologic naïve RA populations 
were estimated for France, Germany and the UK as severe RA patients are assumed 
to be eligible for biologic therapy. Total cost of applying biologic treatment to a 
50% quota of the estimated eligible patient population was compared to a situa-
tion of initiating patients on a biosimilar equivalent with a price point 30% lower 
than the originator. Reinvestment potential was calculated, defining how many 
more patients could be treated with yearly savings. Results: By 2017, when all 3 
biosimilars are expected to be available, the assumed 50% quota resulted in yearly 
savings of € 98 million for the UK, € 351 million for Germany and € 26 million for 
France compared to the budget impact of using the originator. If these savings were 
reinvested potentially 40%, 36% and 39% of the remaining biologic naïve patients 
could be initiated on biosimilar treatment in the UK, Germany and France respec-
tively. ConClusions: The cost savings from biosimilar adoption in naive severe 
RA patients presented potentially increase access by removing budgetary pressures 
from health care systems. Proactive payer encouragement for biosimilar utilization 
is necessary through the use of guidelines and prescription quotas so that health 
care systems can realize significant savings.
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At 18 months, drug survival rate of the mix of first-line biologics was 71.8% [95% 
CI: 60.1% - 80.6%]. ConClusions: Claims database is a useful tool to describe the 
medical management of RA patients. These observations suggest that BA clinical 
use in RA disease management in France is similar to other existing European 
registries data.
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objeCtives: Etanercept 50mg/week (ETN50) has demonstrated efficacy in rheu-
matoid arthritis (RA), psoriatic arthropathy (PA) and ankylosing spondylitis (AS) 
patients. In certain patients in sustained clinical remission, a dose reduction to 
etanercept 25 mg/week (ETN25) could be done. Determine the economic impact 
of ETN25 in RA, PA and AS patients in sustained clinical remission. Methods: 
Observational, retrospective cohort of patients treated with ETN50 that achieve 
and maintain clinical remission (DAS28< 2.6 or BASDAI< 2) during 1 year and slow 
worsening of structural changes, enrolled in an off-label program (January 2006-June 
2013) to switch ETN50 to ETN25. Economical impact was assessed using Enbrel® 
Spanish official prices. Results: From January 2006 to June 1, 2013, 98 RA, 40 PA, 
47 AS patients were treated with ETN50; 39 (24%) patients (18 women; age 53±7 
years; 24 RA, 7 PA, 8 AS) received ETN25 for at least 0.5 years (2.6±2.0 years; range 
0.5-7.3 years). At June 1, 2013, 29 (74%) patients continued on ETN25. RA patients: 17 
continued on ETN25, 5 patients discontinued due to reactivation of RA (4 switched to 
ETN50 and 1 switched to adalimumab, all regained clinical remission) and 2 patients 
due to adverse reactions. PA patients: 4 continued on ETN25, 2 patients discontinued 
due to reactivation of PA (switched to ETN50 regaining clinical remission) and 1 
patient due to adverse reaction. All AS patients continued on ETN25. Total associ-
ated savings with ETN 25 throughout the 7-year observation period were 622.073€ , 
leading to treat 52 additional patients with ETN50 for a year without increasing ETN 
total costs. ConClusions: ETN25 produces cost savings when used in patients 
in clinical remission for at least 1 year with ETN50. At a time when therapy cost is 
an unavoidable component of health care treatment decisions, ETN25 could be a 
cost-effective option for selected RA, PA and AS patients.
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objeCtives: Switching or dose escalation of TNF inhibitors is an option for rheu-
matoid arthritis (RA) patients unresponsive or with a partial response to first-line 
treatment. Drug costs increase with higher dosing but the frequency and impact 
of dose escalation on other costs is not well known. A literature review of biologic 
dose escalation in RA was conducted to assess how often it occurs and the economic 
impact to payers. Methods: A search of PubMed, EMBASE, Cochrane, and Centre of 
Disseminated Reviews was conducted for TNF inhibitors in inflammatory arthritis 
diseases. Searches were focused on dose escalation and economic terms in RA. 
Limits were Human, English and time frame (2003 to 2013). A weighted proportion 
of dose escalators in RA was calculated for each drug as an alternative to reporting 
ranges. Results: Forty-one publications were identified with 36 reporting values 
for dose escalation in RA. The proportion of dose escalators varied widely: adali-
mumab 7.5 to 36%, etanercept 0 to 22%, and infliximab 0 to 80%. Various definitions 
of dose escalation led to the wide range. The weighted proportion of dose escalators 
for each drug was adalimumab 14.9%, etanercept 4.9%, and infliximab 41.7%. Six 
studies reported economic data comparing dose escalators to non-dose escalators. 
Adalimumab drug costs increased 27 to 43% with total costs increasing 28 to 34%; 
infliximab drugs costs increased 6 to 75%, RA-related costs increased 25 to 54%, 
and total costs increased 15% to 35%. Lowest costs were reported with etanercept: 
drug costs increased 3.2 to 19%, RA-related costs increased 4.5%, and total costs 
increased 2.2 to 15%. ConClusions: Pooled results demonstrated dose escalation 
in RA occurred most frequently with infliximab and least frequently with etaner-
cept. Not only were biologic costs increased, but also RA-related and total costs. 
Etanercept was associated with the lowest cost increases.
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objeCtives: This study aimed to describe the rationale for selection of initial bio-
logic therapy and changes in biologic therapy among patients with RA in Germany, 
Spain, and the United Kingdom (UK). Methods: This retrospective, observational 
medical chart review captured patient data via 118 Spanish, German, and British 
rheumatologists. Patients( ≥ 18 years) had a confirmed diagnosis of RA between 
January 2008 and December 2010, and received a biologic therapy for ≥ 3 months and 
had ≥ 12 months of follow-up. Physicians recorded all RA regimens and rationale for 
drug selection. Results: The 656 patients (n= 328; Germany: n= 111, Spain: n= 106, 
UK: n= 111) were 71.3% female, had a mean (standard deviation) age of 48.3 (12.6) 
years at diagnosis and mean 28-joint Disease Activity Score of 5.1±1.2 at biologic 
initiation. Patients most frequently initiated biologic therapy with adalimumab 
(41%) or etanercept (38%). The most common reason for initial biologic treatment 
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by age groups of 60 to 74. ConClusions: The physiotherapy services occurred with 
the highest incidence in cases of the ‘diseases of the musculoskeletal system and 
connective tissue’ ICD group. The dorsopathia diseases at the ICD groups show the 
highest prevalence, indicating the importance of prevention.
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objeCtives: The medical aspects of injuries of the lower extremity is well known, 
however, limited information is available on physiotherapy treatment of these dis-
eases. The aim of our study is to assess amount and frequency of the physiotherapy 
services in hip and thigh injuries based on age and gender distribution. Methods: 
Data were derived from the countrywide database of Hungarian Health Insurance 
Administration (HHIA), based on official reports of outpatient care institutes in 
2009. The total numbers of different physiotherapy services were determined by 
selecting the reported specific diagnoses codes and counting the number treatments 
provided for that specific diagnosis code. The different types of treatment codes 
are listed in the chapter of the Guidelines of HHIA for ‘Physiotherapists, massage-
therapists, conductors and other physiotherapy practices’. The number of cases 
in physiotherapy activities related to for hip and thigh injuries (BNO S70-79) were 
determined per 10,000 persons by age and gender in outpatient care. Results: 
The total number of the 151 different physiotherapy services was 353.260 cases at 
the hip and thigh injuries in the year of 2009 at the. In 2009 the average number of 
cases of physiotherapy activities per 10,000 persons accounted for 351.91 cases. The 
average number of cases per 10,000 persons for males and females were 443.7 cases 
for males and 249.75 cases for females. The number of cases of the hip and thigh 
injuries were higher in the 15-49 age group in males, and in the age group of elderly 
females. ConClusions: In case of the hip and thigh injuries, the highest demand 
of the outpatient care physiotherapy services occurred older injured patients. The 
differences in young males vary with the physical activity and the type of recreation 
activities, and with the condition of osteoporosis in elderly females.
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objeCtives: With an aging population, prevalence of OP and OP-attributable frac-
tures (OAF) is expected to rise dramatically. We evaluated prevalence and treatment 
rates for male OP (MOP) in Germany. Methods: BEST, a retrospective analysis of 
de-identified claims data from a German sickness fund, included male and female 
OP patients, aged ≥ 50 years and insured ≥ 1 day between 01/2006−12/2009. Two 
populations were defined. Inclusion criteria for population B were: 1) OP diagno-
sis (M80.x, M81.x), and/or 2) prescription for OP-related medication (OPM), and 3) 
exclusion of diagnoses M88.x, E83.5x, and M90.7x (ICD-10). Population A included 
population B plus patients solely experiencing OAF. Results: Population A included 
104,938 men. In 2009, prevalence of MOP was 6%. While 67% of men experienced 
≥ 1 OAF during observation period, with the highest rate in those aged 50-54 years 
(78%), only 15% received OPM. Population B included 47,694 men. In 2009 prevalence 
of MOP was 4.8%. 27.2% of those diagnosed experienced ≥ 1 OAF, with the highest 
rate in men aged ≥ 75 years (2006-2009). Only 41.8% of men with ≥ 1 OAF received 
OPM during the observation period. ConClusions: While prevalence of MOP is 
lower than that of postmenopausal OP (6% vs. 24% in 2009), high fracture rates 
in OP-patients represent a significant burden to the German health care system. 
The low treatment rates reported may lead to suboptimal outcomes, and must be 
optimized to reduce risk of follow-up fractures in MOP.
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objeCtives: Using a benefit-harm frontier (BHF) approach, we systematically com-
pared benefits and harms of different HPV- and cytology-based primary cervical can-
cer screening strategies in Germany. Methods: A previously validated and published 
Markov modelwas used to analyze the trade-off between benefits and harms of differ-
ent screening strategies differing by length of screening interval and test algorithms, 
including cytology alone, HPV testing alone, in combination with cytology or with 
cytological triage of HPV-positives. We used published German clinical, epidemio-
logical and international test accuracy data from meta-analyses. Predicted outcomes 
included reduction in cervical cancer incidence and unnecessary treatment (defined 
as conizations of lesions < CIN3). Results: Overall, comparing identical screening 
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objeCtives: The International Costs and Utilities Related to Osteoporotic fractures 
Study (ICUROS) is an ongoing 18 months prospective observational study with the 
objective of estimating resource use and health related quality of life related to 
osteoporotic fractures. This study aims to describe the resource utilization for hip 
fractures (sustained during 2007-2012) pooled from 10 countries: Australia, Austria, 
Estonia, France, Italy, Lithuania, Mexico, Russia, Spain, and the UK. Methods: 
Patients studied were ≥ 50 years and lived at home prior to fracture. Data were col-
lected through patient interviews and review of medical records: at baseline and 4, 
12, and 18 months after fracture. Only resource use related to the fracture event was 
collected. Results: There were 1,795, 1,435, 1,256 patients available for analysis at 4, 
12 and 18 months follow-up, respectively. The mean age (±SD) at fracture was 77±10 
years and 79% were women. 96% of patients were hospitalized. Mean hospital length 
of stay (LoS) (±SD) was 17.2±20.4 days during months 0-4 and 1.2±6.8 during months 
5-18. Mean LoS varied from 9.3 days to 26.5 days during months 0-4 across countries. 
The mean number of physician visits (±SD) was 2.8±3.1 during months 0-4 and 
2.5±5.6 between months 5-18. The mean number of nurse visits (±SD) was 2.4±9.6 
and 3.8±31.9 during corresponding periods, respectively. During months 0-4, 65% of 
patients used analgesics, 41% calcium/vitamin D, and 27% pharmacological inter-
ventions for osteoporosis. The respective uptakes for months 5-18 were 47%, 46% 
and 25%. ConClusions: Almost all patients were hospitalized after fracture and 
the mean number of inpatient days is high, although there is a large variation. The 
vast majority of health care consumption in relation to fracture occurs during the 
first 4 months but substantial consumption persists up to 18 months after fracture.
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objeCtives: The diagnosis and management of PMO involves multiple special-
ists and referrals. To better understand patient management, an ongoing obser-
vational study will evaluate the care map of women with PMO treated in routine 
clinical practice in Switzerland, and estimate the 2-year treatment cost of parenter-
ally administered medications (denosumab, ibandronate, zoledronate). Here, we 
describe the study design and methodology. Methods: Of 52 specialist centers 
across Switzerland operating a DXA machine, 22 agreed to participate in the study. 
Women diagnosed with PMO and initiated on parenteral antiresorptive treatment 
were enrolled in the study between June 18, 2012 and May 31, 2013. To minimize 
selection bias, treatment initiation must have occurred within 6 months before 
study initiation visit at the participating center. The planned follow-up period is 24 
months. Patients may be followed by the specialist or referred back to the general 
practitioner. Where available, the following data will be collected: demographics and 
patient history, co-morbidities and co-medications, DXA T-scores, osteoporosis risk 
factors, PMO treatment and rationale, bone turnover markers, vitamin D level, and 
costs related to PMO diagnosis and treatment. These parameters will be recorded 
at baseline and at any visit in the 24-month observation period as available from 
routine practice. Continuous outcomes will be summarized by descriptive statistics. 
For categorical outcomes, the number and percentage of patients in each category 
will be presented. Baseline covariates (demographic, patient characteristics and site 
characteristics) will be described overall and by treatment received. Results: As 
of May 31, 2013 at least 280 eligible women were enrolled into the study. Full study 
results will be reported at a later date. ConClusions: The recruited number of 
patients confirms the feasibility of the planned methodology. Data from this study 
will provide valuable information regarding the care map of women with PMO in 
routine clinical practice in Switzerland.
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objeCtives: To assess the utilization of out-patient care physiotherapy services 
related to dorsopathia diseases of the musculoskeletal and connective tissue dis-
eases according to age and gender. Methods: The data come from the financial 
data base of the National Health Insurance Fund Administration (in Hungarian: 
OEP) involving the year of 2009. The activity list was provided by the rulebook on 
the application of the activity code list in out-patient care. The dorsopathia dis-
eases of musculoskeletal and connective tissue diseases (M00-M99) are listed in the 
International Classification of Diseases (ICD) with code of M40–M54. The number 
of cases in physiotherapy activities were determined per 10,000 persons by age 
and gender in outpatient care. Results: The total number of the provided 151 dif-
ferent types WHO-classified physiotherapy services was 32.318.413 in the year of 
2009; 19.095.614 (59,09%) of them with the musculoskeletal and connective tissue 
diseases. The prevalence of the dorsopathia diseases were 51,17% in the group of 
the muskuloskeletal and connective tissue diseases. The average number of cases 
of physiotherapy activities per 10,000 persons accounted for 12.015 cases in 2009. 
The average number of cases per 10,000 persons for males and females were 15.589 
cases for males and 8.061 cases for females. The number of cases increase from 
the 20. age groups in the men and women patients. The highest number of physi-
otherapy treatment is provided for both gender in the age group 50 to 59 followed 
